MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00432-026-06546-1

Медицинская библиотека · Journal of cancer research and clinical oncology · 2026

Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.

Tauber Nikolas, Neubacher Melissa, Amann Niklas, P Cieslik Jan, Esposito Irene, Fick Franziska, Freier Catharina, Friebe Verena, Helbig Martina, Hemptenmacher Franziska, Hilmer Lisbeth, Jäger Bernadette, Muras Kerstin, Polkaehn Anna E M, Princk Henriette, Ruckhäberle Eugen, Seidl Maximilian, Fehm Tanja, Rody Achim, Kohls Fabian, Banys-Paluchowski Maggie, Krawczyk Natalia

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Bone marrow carcinomatosis (BMC) is a rare but clinically relevant manifestation of metastatic breast cancer (mBC), characterized by diffuse marrow infiltration and hematologic dysfunction. Evidence on epidemiology, clinical presentation, prognosis, and optimal treatment is limited. We performed a bicentric retrospective real-world analysis of patients diagnosed with BMC, representing the largest reported European cohort to date.

METHODS

We retrospectively analyzed 37 patients diagnosed with BMC at two German university breast cancer centers between 2010 and 2023. Clinical characteristics, hematologic abnormalities, metastatic patterns, treatments, and overall survival (OS) were evaluated. Incidence estimates were calculated based on institutional breast cancer and mBC populations. A systematic literature review contextualized the findings.

RESULTS

The estimated incidence of BMC was 2.6% among patients with mBC and 0.5% among all breast cancer cases. Most patients had HR-positive/HER2-negative disease (89%). Hematologic abnormalities were frequent, including anemia (84%), thrombocytopenia (76%), and pancytopenia (57%). Median OS after BMC diagnosis was 12 months (95% CI 6.0-38.0). Patients with bone-only metastases did not reach median OS, whereas those with additional metastatic sites had a median OS of 9 months (95% CI 5.0-12.0). Patients receiving endocrine therapy plus CDK4/6 inhibition showed numerically longer OS (34 months, 95% CI 5.0-NA) compared with chemotherapy alone (12 months, 95% CI 5.0-38.0).

CONCLUSIONS

BMC remains a rare but challenging complication of mBC. Endocrine-based targeted therapy may improve outcomes in selected HR-positive/HER2-negative patients. Larger multicenter studies are needed to optimize diagnosis and treatment strategies.

Для цитирования: Tauber Nikolas, Neubacher Melissa, Amann Niklas, P Cieslik Jan, Esposito Irene, Fick Franziska, Freier Catharina, Friebe Verena, Helbig Martina, Hemptenmacher Franziska, Hilmer Lisbeth, Jäger Bernadette, Muras Kerstin, Polkaehn Anna E M, Princk Henriette, Ruckhäberle Eugen, Seidl Maximilian, Fehm Tanja, Rody Achim, Kohls Fabian, Banys-Paluchowski Maggie, Krawczyk Natalia. Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.. Journal of cancer research and clinical oncology. 2026. DOI: 10.1007/s00432-026-06546-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.